ASP-8374 clinical trials
Also written ASP8374.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How each study uses ASP-8374 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ASP8374
- 3
Studies by the year they started
3 studies that test it; most in 2017 (1)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2019 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Dana-Farber Cancer Institute (1) · Astellas Pharma Global Development, Inc. (1) · Astellas Pharma Inc (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses ASP-8374 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- ASP8374 + Cemiplimab in Recurrent GliomaCompletedPhase 1Dana-Farber Cancer InstituteNCT04826393Written as ASP8374
- A Multiple-dose Study of ASP8374, an Immune Checkpoint Inhibitor, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsCompletedPhase 1Astellas Pharma Global Development, Inc.NCT03260322Written as ASP8374
- Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid TumorsCompletedPhase 1Astellas Pharma IncNCT03945253Written as ASP8374
Codes
What other systems call ASP-8374 · ClinicalTrials.gg INT018007
- UNII (FDA) TB50XV90MWASP-8374One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | TB50XV90MW | ASP-8374 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.